ASH12 | MM - Case 4


A 65-year-old man with IgG kappa gammopathy, del(13) and lytic bone lesions responds well to bortezomib/D but develops peripheral neuropathy that abates with treatment withdrawal.

If this patient were to again receive bortezomib what would be your likely route of administration and schedule?

To how many patients, if any, have you administered subcutaneous bortezomib?

Do you have patients in your practice right now for whom you think carfilzomib would be beneficial?